Hepatocellular Cancer

P2, N=146, Not yet recruiting, Asan Medical Center

P=N/A, N=400, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University

P2, N=137, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Jun 2026

P2, N=30, Recruiting, University of Miami | Trial completion date: Jan 2031 --> May 2031 | Trial primary completion date: Jan 2031 --> May 2031

P2, N=230, Not yet recruiting, Zhejiang Haichang Biotech Co., Ltd.

Inosine inhibits the activation of the PI3K/AKT signaling pathway. Inosine exerted an inhibitory effect on colorectal cancer liver metastasis by skewing macrophages toward an M1 phenotype, dampening pro-inflammatory cytokine release, and regulating key genes via the PI3K/AKT pathway.

Our findings translate the collective expertise of Chinese physicians into actionable benchmarks for HBV functional cure. The consensus on a minimal 30% cure rate and a preference for combination therapy provide crucial guidance for clinical trial design and the development of novel antiviral strategies.

This study provides the first genomic evidence of shared and divergent somatic mutations in SMARCA4-dNSCLC and its hepatic metastasis. Clonal evolutionary analysis confirmed the diagnosis of SMARCA4-dNSCLC with hepatic metastasis, resolving diagnostic challenges and supporting precision therapy.

Safety assessments in wild-type C57BL/6 mice revealed no significant treatment-related toxicity. To our knowledge, this study is the first to demonstrate in vivo that VB2 alone can significantly suppress hepatic tumorigenesis by enhancing retinol metabolism and inhibiting cell proliferation pathways, highlighting its potential as a chemopreventive agent for HCC.

These data support the PG-CAR-T cells for clinical trial of liver cancer.

In vivo, RRx-001 significantly inhibits tumor growth, enhances T-cell infiltration, promotes M1 macrophage polarization, downregulates PD-L1 expression, and strengthens anti-tumor immunity through T cell-related pathways. With both metabolic and immunomodulatory effects, RRx-001 provides a basis for novel HCC therapies, and future research could explore its synergistic effects with immune checkpoint inhibitors.